NCT06684041View on ClinicalTrials.gov

A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 9, 2024

Primary Completion Date

April 7, 2025

Study Completion Date

April 7, 2025

Conditions

Hemolytic Anemia

Interventions

DRUG

HRS-5965 capsule

DRUG

HRS-5965 capsule placebo

Trial Locations (1)

430071

Zhongnan hospital of Wuhan University, Wuhan

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06684041 - A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects | Biotech Hunter | Biotech Hunter